Skip to main content

Table 1 Clinical data

From: Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany

Variable Children
(8 to 13 years)
(n = 55)
Adolescents
(14 to 17 years)
(n = 41)
Significance level
Sex (male) 43.6% (n = 24) 58.5% (n = 24)  
Age (mean/SD) 10.8/1.7 15.9/1.80  
% vital capacity (mean/SD) 92.5%/11.9% (n = 47) 97.2%/13.1% (n = 34) p = 0.082
% FEV1 (mean/SD) 93.6%/15.2% (n = 47) 90.7%/20.3% (n = 34) p = 0.618
% MEF25 (mean/SD) 68.4%/41.7% (n = 47) 58.9%/37.5% (n = 34) p = 0.273
Bacterial colonization of the lung 63.6% (n = 35) 73.2% (n = 30) p = 0.009
Pneumothorax 1.8% (n = 1) 0% (n = 0) p = 0.392
Allergic bronchopulmonary aspergillosis (ABPA) 3.6% (n = 2) 12.2% (n = 5) p = 0.229
Pancreatic insufficiency 80.0% (n = 44) 78.1% (n = 32) p = 0.782
Hepatobiliary complications 23.6% (n = 13) 26.8% (n = 11) p = 0.840
Distal intestinal obstruction 7.3% (n = 4) 0.0% (n = 0) p = 0.082
Diabetes mellitus 0.0% (n = 0) 7.3% (n = 3) p = 0.041
Nasal polyp 10.9% (n = 6) 17.1% (n = 7) p = 0.366
Isolation obligation for patient 1.8% (n = 1) 9.8% (n = 4) p = 0.081